BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30307363)

  • 1. Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL).
    Galanina N; Kurzrock R
    Cancer Biol Ther; 2019; 20(3):247-251. PubMed ID: 30307363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
    Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
    Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
    Gkotzamanidou M; Papadimitriou CA
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
    d'Amore F; Relander T; Lauritzsen GF; Jantunen E; Hagberg H; Anderson H; Holte H; Österborg A; Merup M; Brown P; Kuittinen O; Erlanson M; Østenstad B; Fagerli UM; Gadeberg OV; Sundström C; Delabie J; Ralfkiaer E; Vornanen M; Toldbod HE
    J Clin Oncol; 2012 Sep; 30(25):3093-9. PubMed ID: 22851556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment.
    Kitahara H; Maruyama D; Maeshima AM; Makita S; Miyamoto KI; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Tajima K; Terauchi T; Kurihara H; Taniguchi H; Komatsu N; Tobinai K
    Ann Hematol; 2017 Mar; 96(3):411-420. PubMed ID: 27928587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Advances in the Treatment of Peripheral T-Cell Lymphoma.
    Laribi K; Alani M; Truong C; Baugier de Materre A
    Oncologist; 2018 Sep; 23(9):1039-1053. PubMed ID: 29674443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.
    Mak V; Hamm J; Chhanabhai M; Shenkier T; Klasa R; Sehn LH; Villa D; Gascoyne RD; Connors JM; Savage KJ
    J Clin Oncol; 2013 Jun; 31(16):1970-6. PubMed ID: 23610113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation.
    Prochazka V; Faber E; Raida L; Vondrakova J; Kucerova L; Jarosova M; Indrak K; Papajik T
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):63-6. PubMed ID: 19365529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
    Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
    Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified.
    Kim S; Kwon D; Koh J; Nam SJ; Kim YA; Kim TM; Kim CW; Jeon YK
    Virchows Arch; 2020 Jul; 477(1):131-142. PubMed ID: 32170448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone Marrow Transplantation for Peripheral T-Cell Non-Hodgkins' Lymphoma in First Remission.
    Sharma M; Pro B
    Curr Treat Options Oncol; 2015 Jul; 16(7):34. PubMed ID: 26076798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
    Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
    Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas.
    Yam C; Landsburg DJ; Nead KT; Lin X; Mato AR; Svoboda J; Loren AW; Frey NV; Stadtmauer EA; Porter DL; Schuster SJ; Nasta SD
    Am J Hematol; 2016 Jul; 91(7):672-6. PubMed ID: 27012928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide.
    Yamaguchi M; Kotani T; Nakamura Y; Ueda M
    Int J Hematol; 2006 Jun; 83(5):450-3. PubMed ID: 16787878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Composite Lymphoma as Co-occurrence of Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Carrying Trisomy 12 and t(14;18) and Peripheral T-cell Lymphoma.
    Aoyama Y; Kodaka T; Zushi Y; Goto Y; Tsunemine H; Itoh T; Takahashi T
    J Clin Exp Hematop; 2018 Mar; 58(1):27-31. PubMed ID: 29415977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation.
    Kahl C; Leithäuser M; Wolff D; Steiner B; Hartung G; Casper J; Freund M
    Ann Hematol; 2002 Nov; 81(11):646-50. PubMed ID: 12454703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.
    Kim SJ; Yoon DH; Kang HJ; Kim JS; Park SK; Kim HJ; Lee J; Ryoo BY; Ko YH; Huh J; Yang WI; Kim HK; Min SK; Lee SS; Do IG; Suh C; Kim WS;
    Eur J Cancer; 2012 Nov; 48(17):3223-31. PubMed ID: 22770877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement.
    Visco C; Medeiros LJ; Jones D; Smith T; Rodriguez MA; McLaughlin P; Romaguera J; Cabanillas F; Sarris AH
    Ann Oncol; 2002 Aug; 13(8):1290-9. PubMed ID: 12181254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas.
    Niitsu N; Okamoto M; Nakamine H; Aoki S; Motomura S; Hirano M
    Hematol Oncol; 2008 Sep; 26(3):152-8. PubMed ID: 18395866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.